

VOL 113, NO. 11

NOVEMBER 1977

ORIGINAL CONTRIBUTIONS

Vitiligo and Juvenile Diabetes Mellitus

Chamel Macaron, MD; Robert J. Winter, MD; Howard S. Traisman, MD;
Barry D. Kahan, MD; Alan E. Lasser, MD; Orville C. Green, Chicago 1515

HLA-A10 in Pemphigus Among Japanese

Koji Hashimoto, MD, Osaka, Japan; Yoshiharu Miki, MD, Shigenobucho, Japan;
Seizo Nakata, MD; Masamichi Matsuyama, MD, Osaka, Japan 1518

Oral Pemphigus Vulgaris

Michael Meurer, MD; John L. Millns, MD; Roy S. Rogers III, MD;
Robert E. Jordon, MD, Rochester, Minn 1520

Treatment of Psoriasis With Long-Wave Ultraviolet Light

John A. Parrish, MD, Boston 1525

Photochemotherapy of Psoriasis Using Methoxsalen and Sunlight

John A. Parrish, MD, Boston;
H. Anthony D. White, MB, BS, FRACP, Sydney, Australia;
Timothy Kingsbury, Boston; Mahmoud Zahar, MD, Taif, Saudi Arabia;
Thomas B. Fitzpatrick, MD, Boston 1529

Smokers' Melanosis

C. Anders Hedin, DDS, Centrallasarettet Eskilstuna, Sweden 1533

Topically Applied Antifungal Agents

Sylvia M. Wallace, PhD; Vinod P. Shah, PhD; William L. Epstein, MD;
Joseph Greenberg, MD; Sidney Riegelman, PhD, San Francisco 1539

Cell Populations in Experimental Contact Dermatitis

Nicole Hunziker, MD, Richard K. Winkelmann, MD, PhD, Rochester, Minn 1543

Topical Treatment of Herpes Labialis With Chloroform

Cynthia A. Taylor, MD; J. Owen Hendley, MD; Kenneth E. Greer, MD;
Jack M. Gwaltney, Jr, MD, Charlottesville, Va 1550

CASE REPORTS

Erythropoietic Porphyria

George S. Stretcher, MD, Augusta, Ga 1553

Ulcers of the Leg in Thalassemia

Dwight M. Stevens, MD; Jerome L. Shupack, MD;
Jamshid Javid, MD; Robert Silber, MD, New York 1558

DeSanctis-Cacchione Syndrome

William B. Reed, MD, Irvine, Calif; Gerald I. Sugarman, MD, Los Angeles;
Reed A. Mathis, Madison, Wis 1561

Acquired Perilungual Fibrokeratoma

Ronald L. Cahn, MD, Stanford, Calif 1564

Fatal Cytomegalic Inclusion Disease

Norman Minars, MD; Jan F. Silverman, MD; Mario R. Escobar, PhD;
A. Julio Martinez, MD, Richmond, Va 1569

Halo Congenital Nevus

Martin H. Brownstein, MD; Bonnie B. Kazam, MD, New York;
Ken Hashimoto, MD, Memphis 1572

Atypical Multicentric Reticulohistiocytosis With Paraproteinemia

Jonathan R. S. Rendall, MRCP; Robert I. Vanhegan, BM, DPhil;
Alastair H. T. Robb-Smith, MD, FRCP, Oxford, England;
Robert E. Bowers, MD, FRCP, Gloucester, England; Terence J. Ryan, FRCP;
Henry R. Vickers, MD, FRCP, Oxford, England 1576

(Continued on page 1484)

EDITORIAL BOARD

Chief Editor
John H. Epstein, MD
450 Sutter Street
San Francisco 94108

Assistant Chief Editor
Kimie Fukuyama, MD
San Francisco

Assistant Chief Editor
Denny L. Tuffanelli, MD
San Francisco

Donald C. Abele, MD
Augusta, Ga.

Harry L. Arnold, Jr, MD
Honolulu

Walter C. Lobitz, Jr, MD
Portland, Ore

Frederick D. Malkinson, MD
Chicago

Sigfrid A. Muller, MD
Rochester, Minn

W. Mitchell Sams, Jr, MD
Chapel Hill, NC

John S. Strauss, MD
Boston

Morris Waisman, MD
Tampa, Fla

Gerald D. Weinstein, MD
Miami

Ulcerative Systematized Porokeratosis (Mibelli)
 Enthi M. Abdul Razack, MD, DD,
 Marthandam Natarajan, MD, ZDV, FDS, Madras, India 1583

Recurrent Pyoderma Gangrenosum and Agnogenic Myeloid Metaplasia
 Jeffrey P. Callen, MD; Howard V. Dubin, MD;
 Charles F. Gehrke, MD, Ann Arbor, Mich 1585

Cobb Syndrome
 R. Thomas Jessen, MD; Stephen Thompson, MD;
 Edgar B. Smith, MD, Albuquerque, NM 1587

Diffuse Eosinophilic Fasciitis
 Victor M. Torres, MD, William M. George, MD, Miami 1591

REGULAR DEPARTMENTS

Short Reports 1598

Benign Mucous Membrane Pemphigoid Harold J. Brody, MD, Donald J. Pirozzi, MD, Atlanta . . . **Serratia marcescens Cellulitis** Dean E. Brenner, MD, Donald P. Lookingbill, MD, Hershey, Pa . . . **Tinea Capitis Due to Trichophyton soudanense** Donald R. Cox, MD, Fritz Blank, DSc Nat, Philadelphia

Books 1604

News and Notes 1605

Letters to the Editor 1610

Percutaneous Penetration Following Use of Hair Dyes Robert S. Yare, PhD; Mario Garcia, PhD, Stamford, Conn; Howard I. Maibach, MD, San Francisco; M. A. Leaffer, MS; W. A. Skinner, PhD, Menlo Park, Calif . . . **Rifampin in Leishmaniasis** F. Rolando Vásquez, MD, Guatemala City . . . **Photosensitivity Owing to Thiourea** J. C. Van der Leun, PhD; E. J. de Kreek, MD; M. Deenstra-van Leeuwen, MD, H. van Weelden, MSc, Utrecht, The Netherlands . . . **Transient Acantholytic Dermatitis** Reed R. Lockwood, MD; Peter M. Elias, MD, San Francisco; Margaret Waisman, MD, Houston . . . **Ocular Involvement in Pyoderma Gangrenosum** Rudolf Happle, MD; Hans-Peter Schiffer, MD; Peter M. Kövary, MD, Münster, West Germany . . . **Macular Anetoderma in an Appendectomy Site** André Dupré, MD, Toulouse, France . . . **Toxic Epidermal Necrolysis in Patients Who Are Allergic to Penicillin** Jata S. Ghosh, MS, Ardmore, Pa . . . **Vertical Striated Sandpaper Nails** Robert Baran, MD, Cannes, France, André Dupré, MD, Toulouse, France . . . **Paraneoplastic Acrokeratosis of Bazex** Robert Baran, MD, Cannes, France . . . **Bullous Erythema Multiforme** Howard S. Yaffee, MD, Cambridge, Mass . . . **Chronic Bullous Dermatitis of Childhood** David A. Voron, MD; Arcadia, Calif; Nancy B. Esterly, MD; Nancy L. Furey, MD, Chicago . . . **Nail Polish Remover Sensitization** Lawrence M. Field, MD, San Luis Obispo, Calif . . . **Contaminated Fungal Cultures Owing to Tyrophagus putrescentiae** Robert B. Amon, MD; Jon M. Hanifin, MD; Mary C. Campbell, Portland, Ore . . . **Clarification of Lichen Planus Actinicus** Sylvia Martin, MD, Vancouver, British Columbia; Mouta Dilaimy, MD, Baltimore . . . **An Unusual Variant of Darier's Disease: A Therapeutic Suggestion** Samuel Ayres, Jr, MD, Richard Mihan, MD, Los Angeles . . . **Griseofulvin Therapy in Molluscum Contagiosum** Om P. Singh, MD, DVD, Amrinder J. Kanwar, MD, New Delhi . . . **Treatment of Atopic Dermatitis With the Scholtz Regimen** Samuel Ayres, Jr, MD, Richard Mihan, MD, Los Angeles . . . **Dapsone-Induced Hepatic Changes** Lt Col D. Klaus Goette, MD, USA, Presidio of San Francisco, Calif . . . **Lymphomatoid Papulosis** Warren L. Macaulay, MD, Fargo, ND, Kristian Thomsen, MD, Copenhagen

Society Transactions 1622

Index to Advertisers 1634

Instructions for Authors 1490

SYNALAR®
 (fluocinolone acetonide)
 CREAM 0.025%
 CREAM 0.01%
 OINTMENT 0.025%
 SOLUTION 0.01%

Description Synalar (fluocinolone acetonide) has the chemical name 6 α , 9 α -difluoro-16 α -hydroxyprednisolone-16, 17-acetonide.

The cream contains fluocinolone acetonide 0.25 mg./g. or 0.1 mg./g. in a water-washable aqueous base of stearic acid, propylene glycol, sorbitan monostearate and monooleate, polysorbate 60, purified water and citric acid with methylparaben and propylparaben as preservatives.

The ointment contains fluocinolone acetonide 0.25 mg./g. in a white petrolatum U.S.P. vehicle.

The solution contains fluocinolone acetonide 0.1 mg./g. in a water-washable base of propylene glycol with citric acid.

Indications For relief of the inflammatory manifestations of corticosteroid-responsive dermatoses.

Contraindications Topical steroids are contraindicated in vaccinia and varicella.

Topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Precautions If irritation develops, the product should be discontinued and appropriate therapy instituted.

In the presence of an infection the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

If extensive areas are treated or if the occlusive technique is used, the possibility exists of increased systemic absorption of the corticosteroid and suitable precautions should be taken.

Although topical steroids have not been reported to have an adverse effect on pregnancy, the safety of their use in pregnant females has not absolutely been established. Therefore, they should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Synalar products are not for ophthalmic use.

Adverse reactions The following local adverse reactions have been reported with topical corticosteroids: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneform eruptions, hypopigmentation.

The following may occur more frequently with occlusive dressings than without such therapy: maceration of the skin, secondary infection, skin atrophy, striae, miliaria.

How Supplied
 Synalar (fluocinolone acetonide)
 Cream 0.025% — 15 and 60g. tubes and 120 and 425g. jars.
 Cream 0.01% — 15, 45 and 60g. tubes and 120 and 425g. jars.
 Ointment 0.025% — 15 and 60g. tubes and 425g. jars.

Solution 0.01% — 20cc. and 60cc. plastic squeeze bottles.

Also Available
 Synalar-HP® (fluocinolone acetonide)
 Cream 0.2% 5g. and 12g. tubes.

SUBSCRIPTION RATES: The yearly rate of the ARCHIVES OF DERMATOLOGY is as follows: United States and US Possessions, one year, \$18; two years, \$28; all other countries, one year, \$28; two years, \$38. Special yearly price to residents, interns and medical students in the United States and US Possessions, \$9.

THE ARCHIVES OF DERMATOLOGY is published monthly by the American Medical Association, 535 N Dearborn St, Chicago, IL 60610, and is an official publication of the Association. Second-class postage paid at Chicago and at additional mailing office.